Olema Pharmaceuticals Stock Performance
| OLMA Stock | USD 4.60 0.06 1.29% |
The company holds a Beta of 3.01, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Olema Pharmaceuticals will likely underperform. At this point, Olema Pharmaceuticals has a negative expected return of -1.16%. Please make sure to check Olema Pharmaceuticals' total risk alpha, kurtosis, price action indicator, as well as the relationship between the value at risk and rate of daily change , to decide if Olema Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Olema Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 23.7 M |
Olema |
Olema Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,012 in Olema Pharmaceuticals on November 28, 2024 and sell it today you would lose (550.50) from holding Olema Pharmaceuticals or give up 54.4% of portfolio value over 90 days. Olema Pharmaceuticals is currently does not generate positive expected returns and assumes 5.5338% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Olema, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Olema Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Olema Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Olema Pharmaceuticals, and traders can use it to determine the average amount a Olema Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2104
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OLMA |
Estimated Market Risk
| 5.53 actual daily | 49 51% of assets are more volatile |
Expected Return
| -1.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Olema Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Olema Pharmaceuticals by adding Olema Pharmaceuticals to a well-diversified portfolio.
Olema Pharmaceuticals Fundamentals Growth
Olema Stock prices reflect investors' perceptions of the future prospects and financial health of Olema Pharmaceuticals, and Olema Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Olema Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 132.17 M | ||||
| Shares Outstanding | 74.24 M | ||||
| Price To Book | 1.74 X | ||||
| EBITDA | (104.58 M) | ||||
| Cash And Equivalents | 240.71 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 2.42 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 3.48 X | ||||
| Cash Flow From Operations | (83.73 M) | ||||
| Earnings Per Share | (2.28) X | ||||
| Total Asset | 276.94 M | ||||
| Retained Earnings | (305.63 M) | ||||
About Olema Pharmaceuticals Performance
By analyzing Olema Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Olema Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Olema Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Olema Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for womens cancers. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Olema Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.Things to note about Olema Pharmaceuticals performance evaluation
Checking the ongoing alerts about Olema Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Olema Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Olema Pharmaceuticals generated a negative expected return over the last 90 days | |
| Olema Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (96.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Olema Pharmaceuticals currently holds about 240.71 M in cash with (83.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Olema Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors |
- Analyzing Olema Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Olema Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Olema Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Olema Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Olema Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Olema Pharmaceuticals' stock. These opinions can provide insight into Olema Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Olema Stock analysis
When running Olema Pharmaceuticals' price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |